Message from CEO

“Financial results for the first quarter of FY2017 were in line with our expectations and the previously announced consolidated forecasts. Although some development programs were discontinued, the rest of our development activities are progressing steadily, and the acquisition of Ogeda expanded Astellas’ late-stage clinical pipeline including fezolinetant,” said Yoshihiko Hatanaka, president and CEO, Astellas. “We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan through maximizing the product value, creating innovation and pursuing operational excellence.”

Stock Quotes(TSE 1st:4503)

View Stock Performance

IR Library

This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.

Read More

Stock & Rating Information

Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash divid...

Read More

Analyst Coverage

List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc

Read More

Cautionary Statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including sh...

Read More
Vision & Strategy

On the forefront of healthcare change to turn innovative science into value for patients.


We introduce the progress of our clinical development projects called "R&D pipeline". We update R&D pipeline 4 or 5 times annually in our quarterly performance reports.

Clinical Trials

This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any products. This site includes information regarding products sold by Astellas in certain countries in the world. However, some of those products are not approved by the regulatory authorities of other countries. For details, please refer to the full Legal Disclaimer.